share_log

Hologic's (NASDAQ:HOLX) Soft Earnings Don't Show The Whole Picture

Hologic's (NASDAQ:HOLX) Soft Earnings Don't Show The Whole Picture

Hologic(納斯達克股票代碼:HOLX)的軟收益並不能顯示全貌
Simply Wall St ·  05/11 10:55

Shareholders appeared unconcerned with Hologic, Inc.'s (NASDAQ:HOLX) lackluster earnings report last week. We think that the softer headline numbers might be getting counterbalanced by some positive underlying factors.

股東們似乎對Hologic, Inc.毫不關心。”s(納斯達克股票代碼:HOLX)上週的收益報告乏善可陳。我們認爲,較疲軟的標題數字可能會被一些積極的潛在因素所抵消。

earnings-and-revenue-history
NasdaqGS:HOLX Earnings and Revenue History May 11th 2024
NASDAQGS: HOLX 收益和收入歷史記錄 2024 年 5 月 11 日

The Impact Of Unusual Items On Profit

不尋常物品對利潤的影響

To properly understand Hologic's profit results, we need to consider the US$362m expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. In the twelve months to March 2024, Hologic had a big unusual items expense. As a result, we can surmise that the unusual items made its statutory profit significantly weaker than it would otherwise be.

爲了正確理解Hologic的利潤業績,我們需要考慮歸因於不尋常物品的3.62億美元支出。看到不尋常的項目使公司利潤損失從來都不是一件好事,但從好的方面來看,情況可能遲早會好轉。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。鑑於這些單列項目被認爲不尋常,這並不奇怪。在截至2024年3月的十二個月中,Hologic有一筆不尋常的巨額物品支出。因此,我們可以推測,這些不尋常的物品使其法定利潤明顯低於原來的水平。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On Hologic's Profit Performance

我們對Hologic利潤表現的看法

As we mentioned previously, the Hologic's profit was hampered by unusual items in the last year. Based on this observation, we consider it possible that Hologic's statutory profit actually understates its earnings potential! On the other hand, its EPS actually shrunk in the last twelve months. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So while earnings quality is important, it's equally important to consider the risks facing Hologic at this point in time. While conducting our analysis, we found that Hologic has 2 warning signs and it would be unwise to ignore these.

正如我們之前提到的,去年,Hologic的利潤因不尋常的項目而受到阻礙。基於這一觀察,我們認爲Hologic的法定利潤實際上可能低估了其盈利潛力!另一方面,其每股收益實際上在過去十二個月中萎縮了。歸根結底,如果你想正確地了解公司,必須考慮的不僅僅是上述因素。因此,儘管收益質量很重要,但考慮Hologic目前面臨的風險同樣重要。在進行分析時,我們發現Hologic有兩個警告信號,忽略這些信號是不明智的。

Today we've zoomed in on a single data point to better understand the nature of Hologic's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天,我們放大了單個數據點,以更好地了解Hologic利潤的性質。但是,還有很多其他方法可以讓你對公司的看法。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 “關注資金”,尋找內部人士正在買入的股票。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論